Rezolute (RZLT) reported a net loss of $20.5 million, or $0.20 per basic and diluted share, for the fourth quarter of fiscal 2026 ended June 30. The company reported cash, cash equivalents and marketable securities of $107.8 million at June 30, 2026.
For fiscal 2026, Rezolute recorded a net loss of $77.6 million. The company said enrollment in its Phase 3 upLIFT study in tumor hyperinsulinism is ongoing, with topline results expected before the end of 2026.
- Fourth-quarter R&D expense was $14.9 million, compared with $20.9 million a year earlier.
- Fourth-quarter G&A expense was $6.7 million, compared with $5.0 million a year earlier.
- Fiscal 2026 R&D expense totaled $53.8 million, while G&A expense totaled $29.2 million.
- In the upLIFT study, seven participants had met the responder criterion for the primary endpoint, while one participant was counted as a non-responder.
- Rezolute said its Phase 3 sunRIZE congenital hyperinsulinism data remains under FDA review.
$RZLT Insider Trading Activity
$RZLT insiders have traded $RZLT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RZLT stock by insiders over the last 6 months:
- DARON EVANS (CFO) purchased 10,000 shares for an estimated $28,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RZLT Hedge Fund Activity
We have seen 96 institutional investors add shares of $RZLT stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JACOBS LEVY EQUITY MANAGEMENT, INC added 2,341,247 shares (+1062.2%) to their portfolio in Q2 2026, for an estimated $12,174,484
- BANK OF AMERICA CORP /DE/ removed 2,240,217 shares (-75.4%) from their portfolio in Q2 2026, for an estimated $11,649,128
- STATE STREET CORP removed 2,209,867 shares (-55.5%) from their portfolio in Q1 2026, for an estimated $6,740,094
- D. E. SHAW & CO., INC. added 1,589,967 shares (+637.5%) to their portfolio in Q2 2026, for an estimated $8,267,828
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC removed 1,500,000 shares (-75.0%) from their portfolio in Q2 2026, for an estimated $7,800,000
- UBS GROUP AG removed 1,442,021 shares (-74.4%) from their portfolio in Q2 2026, for an estimated $7,498,509
- BLACKROCK, INC. added 1,404,788 shares (+22.3%) to their portfolio in Q2 2026, for an estimated $7,304,897
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
